Related Experiment Video
Updated: Feb 4, 2026

In Vitro Thrombosis Test for Ventricular Assist Devices
Published on: March 21, 2025
Postoperative bridging anticoagulation and left ventricular assist system thrombosis
David M Nemer1, Garrick C Stewart2, Maneka Puligandla3
1Department of Cardiovascular Medicine, Cleveland Clinic Foundation, 9500 Euclid Avenue, Desk J3-129, Cleveland, OH, 44195, USA. nemerd@ccf.org.
Reduced emphasis on early postoperative bridging anticoagulation may increase HeartMate II pump thrombosis. Therapeutic anticoagulation bridges may lower 6-month thrombosis risk, but overall incidence remains unchanged. Further research is needed.
Area of Science:
- Cardiology
- Biomedical Engineering
Background:
- HeartMate II (HM II) pump thrombosis incidence has increased.
- Reduced emphasis on early postoperative bridging anticoagulation is a suspected cause.
Purpose of the Study:
- To analyze initial postoperative anticoagulation practices and their impact on HM II pump thrombosis incidence.
Main Methods:
- Single-center analysis of 105 primary HM II implant patients (2009-2014).
- Defined parenteral bridge as anticoagulation before INR ≥ 2 on warfarin.
- Characterized bridges as early (≤3 days) and therapeutic (goal PTT for 3 days).
- Pump thrombosis "suspected" clinically, "confirmed" by device visualization.
Main Results:
- 70% received parenteral bridge, 68% started within 3 days.
- Therapeutic PTT achieved in 52% of bridged patients.
- Lower INTERMACS profiles and longer ICU stay in bridged patients.
- 6-month suspected thrombosis: 15.8% with therapeutic bridge vs. 29.9% without.
- 6-month confirmed thrombosis: 7.9% with therapeutic bridge vs. 16.4% without.
- Trend not sustained at 12 and 24 months; no overall difference in pump thrombosis incidence.
Conclusions:
- Initial postoperative parenteral bridging anticoagulation is common but often sub-therapeutic.
- Therapeutic bridging may reduce 6-month pump thrombosis but not overall incidence.
- Anticoagulation strategies require optimization for HeartMate II device safety.
Related Concept Videos
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Design Example: Strain Gauge Bridge or Wheatstone Bridge
Wheatstone Bridge
Thus, for accurate resistance measurements, a...
Bridge rectifier
Operationally, the bridge rectifier allows current flow through two of its diodes during each...
Venous Thrombosis I: Introduction
Cross-bridge Cycle

